Polish medtech company Medicalgorithmics (MDG) has entered into an agreement with Fourth Frontier, enabling its innovative DeepRhythm Platform (DRP), combined with the DeepRhythmAI (DRAI) artificial intelligence algorithms, to be offered alongside Fourth Frontier’s unique device – a multi-day Holter monitor in the form of a wearable band, recently certified by the FDA. The goal is to facilitate Medicalgorithmics’ software in monitoring up to 100,000 patients connected to the Holter device within the first 12 months. One of the initial adopters of the solution will be Cleveland Clinic, a leading U.S. medical center.
The DRAI algorithm suite, combined with the DRP platform, represents the next generation of Medicalgorithmics’ products, offering high performance, scalability, and security in cardiac arrhythmia diagnostics. Both innovative solutions have already received certification for the U.S. market (FDA clearance) and the European market (CE marking). Medicalgorithmics provides its DRAI algorithms to clients in the U.S. and Europe either as a standalone product or integrated with the DRP platform, enabling physicians and ECG technicians rapid access to diagnostic analysis. Both solutions have already been successfully commercialized with initial clients.
“The U.S. is our largest and most strategic market, and this newly signed agreement will significantly expand our software’s presence in the country. Our partner aims to reach and serve 100,000 patients within the first 12 months following the integration of its device with our platform. One of the first institutions to utilize our software in conjunction with Fourth Frontier’s Holter monitors will be Cleveland Clinic. Moreover, additional prestigious U.S. medical centers—including Mayo Clinic, the University of San Francisco, and Johns Hopkins University—have already expressed interest in our solution,” commented Jarosław Jerzakowski, Board Member and Chief Operating & Sales Officer at Medicalgorithmics.
Fourth Frontier’s solutions are already utilized in leading healthcare systems worldwide, including One Welbeck in the United Kingdom and among patients under the care of Cleveland Clinic in the U.S. The company’s health and wellness product line has been adopted by over 18,000 users, who continuously monitor their cardiac health. Additionally, the FX Plus Holter monitor is actively used by leading sports cardiologists, cardiac rehabilitation specialists, and research universities globally.
Medicalgorithmics’ DeepRhythm Platform (DRP) is a cloud-based system that leverages cutting-edge technologies to deliver high-performance, scalable, and secure cardiac arrhythmia diagnostics. By integrating next-generation DeepRhythmAI (DRAI) algorithms – best-in-class artificial intelligence models -DRP offers high diagnostic accuracy and the flexibility to analyze data from various ECG recorders used worldwide for arrhythmia detection.
The DRAI algorithms have been trained on over 3.6 million days of ECG recordings, making them one of the most advanced solutions of their kind globally. Their effectiveness was validated in the DRAI MARTINI study, presented in early September 2024 at the ESC Congress 2024 in London, the largest cardiology conference in Europe. Conducted on a cohort of over 14,000 patients, with participation from more than 50 cardiologists from the U.S., Canada, and Europe, the study demonstrated that DRAI algorithms make 14 times fewer errors in ECG data analysis and the identification of critical arrhythmia cases compared to trained ECG technicians. This groundbreaking study on AI in medicine, based on an extensive patient sample, was published in February in Nature Medicine, a leading medical journal.